BAX Expression in Colorectal Cancer Cells Exposed to Aspirin and Novel Aspirin Analogues

Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) have long been used in the treatment of colorectal cancer and other neoplasm whose underlying efficacy and biomolecular mechanism is generally believed to be through induction of Bax protein among others resulting in cell apoptosis but its toxicity precludes its chemotherapeutic benefits. However, there exists a dearth of knowledge on the use of other more efficacious and more tolerable novel aspirin analogues with better prognosis. The purpose of this study was to investigate Bax induction on SW480 cells treated with 0.5mM aspirin and novel aspirin analogues; PN508 (bis-carboxylphenol-succinate), PN517 (Fumaroyldiasprin) and PN529 (Isopropyl m- bromobenzoylsalicylate) measured after 48 hours of incubation at 370C using analytical digital photomicroscopy.
The results of this study showed a 60-70% folds increase in Bax expression in 0.5mM Aspirin treated cells. 0.5mM PN517 and PN529 treated cells showed 70-80% folds increases in Bax expression whilst 0.5mM PN508 treated cells showed a significance of 100-120% folds increase in Bax expression.
This study reports that 0.5mM aspirin and novel aspirin analogues PN508, PN517 and PN529 caused increase in Bax expression when exposed to SW480 cells at 370C for 48 hours. It could be inferred from the results of this study that novel aspirin analogues PN508, PN517 and PN529 are potentially more potent inducers of Bax protein than aspirin in SW480 cells.
We therefore recommend that these novel aspirin analogues be considered in designing alternative and more efficacious drugs for the treatment of colorectal cancer and other neoplasm in the nearest future.

Bax, Aspirin, Aspirin Analogues, Collorectal cancer cells (SW480 CELLS)

1. Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C., and Parkin, D.M. (2010) GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC Cancer Base NO.10. Lyon France: international Agency for Research on cancer [Google Scholar] [Crossref]

2. Boyle, P. and Levin, B. (2008) Word Cancer Report. World Health Organization [Google Scholar] [Crossref]

3. Baena, R., & Salinas, P. (2015). Diet and colorectal cancer. Maturitas, 80(3), 258-264. [Google Scholar] [Crossref]

4. Kikuchi, N., Nishiyama, T., Sawada, T., Wang, C., Lin, Y., Watanabe, Y., ... & Kikuchi, S. (2017). Perceived stress and colorectal cancer incidence: the Japan collaborative cohort study. Scientific reports, 7(1), 40363. [Google Scholar] [Crossref]

5. Office of national statistics , (2010) Cancer statistics registrations (ISD): registration of cancer diagnosed in 2007 [Google Scholar] [Crossref]

6. Altekruse, S.F., Kosary, C.L., Krapcho, M., Neyman, N., Aminou, R., Waldron, W., Ruhl, J., Howlader, N., Talalovich, Z., Cho, H., Mariotto, A., Eisner, M.P., Lewis, D.R., Cronin, K., Chen, H.S., Feuer, E.J., Stinchcomb, D.G. and Edwards, B.K. (2009). SEER CANCER Statistics Review, 1975-2007. National Cancer institute Bethesda. Posted to the SEER web 20 year survey-1971 to1990. Hepatogastroenterology, 47: pp.709-13. [Google Scholar] [Crossref]

7. Tazinkeng, N. N., Pearlstein, E. F., Manda-Mapalo, M., Adekunle, A. D., Monteiro, J. F. G., Sawyer, K., ... & Asombang, A. W. (2024). Incidence and risk factors for colorectal cancer in Africa: a systematic review and meta-analysis. BMC gastroenterology, 24(1), 303. [Google Scholar] [Crossref]

8. Segal, I. (1998) Rarity of colorectal adenomas in the African black population. European Journal Cancer preview, 7: pp.351 -2 [Google Scholar] [Crossref]

9. Onyoh, E. F., Hsu, W. F., Chang, L. C., Lee, Y. C., Wu, M. S., & Chiu, H. M. (2019). The rise of colorectal cancer in Asia: epidemiology, screening, and management. Current gastroenterology reports, 21(8), 36. [Google Scholar] [Crossref]

10. Mecklin, J.P. (2008) The implications of genetics in colorectal cancer. Ann Oncol, 19(Suppl 5): pp.87-90 [Google Scholar] [Crossref]

11. Norat, T. (2005) Meat, fish and colorectal cancer risk: the European prospective investigation into cancer and nutrition. Journal of National cancer institute, 97(12): pp.906-16 [Google Scholar] [Crossref]

12. Larsson, S.C., Orsini, N. and Wolk, A. (2005) Diabetes mellitus and risk of colorectal cancer: a meta-analysis. Journal of national Cancer Institute, 97(22): pp.1679-87 [Google Scholar] [Crossref]

13. Nguyen, L., & Shanmugan, S. (2025). A review article: the relationship between obesity and colorectal cancer. Current Diabetes Reports, 25(1), 8. [Google Scholar] [Crossref]

14. Moskal, (2007) Alcohol intake and colorectal cancer risk: A dose-response meta-analysis of published cohort studies. International Journal of Cancer, 120(3): pp.664-71 [Google Scholar] [Crossref]

15. Chung, D.C. (2000) The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterology, 119: pp.854-865 [Google Scholar] [Crossref]

16. Testa, U., Pelosi, E., & Castelli, G. (2018). Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells. Medical Sciences, 6(2), 31. [Google Scholar] [Crossref]

17. Chan, A.T. (2003) Aspirin, non-steroidal anti-inflammatory drugs and colorectal neoplasia: future challenges in chemoprevention. Cancer Causes Control, 14: pp.413-418 [Google Scholar] [Crossref]

18. Baron, J.A., Cole, B.F. and Sandler R.S. (2003) A randomized trial of aspirin to prevent colorectal cancer. New England Journal of Medicine, 348: pp.891-899 [Google Scholar] [Crossref]

19. Sandler, R.S., Halabi, S., and Baron, J.A. (2003) A randomized trial of aspirin to prevent colorectal cancer adenomas in patients with previous colorectal cancer. New England Journal of Medicine, 348: pp.883-890 [Google Scholar] [Crossref]

20. Zhang, H. and Sun, X.F. (2002) Over expression of cyclooxygenase-2 correates with advanced stages of colorectal cancer. American Journal of Gastroenterology, 97: pp.1037-1041ss [Google Scholar] [Crossref]

21. Brown, J.R. and DuBois, R.N. (2005) COX-2: a molecular target for colorectal cancer prevention. Journal of Clinical Oncology, 23: pp.2840-2855 [Google Scholar] [Crossref]

22. Greten, F.R., Eckmann, L., Greten, T.F., Park, J.M., Li, Z.W., Egan, L.J., Kagnoff, M.F. and Karin, M. (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell, 118(3): pp.285-96 [Google Scholar] [Crossref]

23. Patron, C., Garcia, Rodriquez, L.A., Landolfi, R. and Baigent, C. (2005) Low dose aspirin for the prevention of atherothrombosis. New England Journal of Medicine, 353: pp.2373-2383 [Google Scholar] [Crossref]

24. Priyanka, Dikshit, Mou, Chatterjee, Anand, Goswanmi, Amit, Mishra, Nihar, Ranjan and Jana, (2006) Aspirin induces apoptosis through inhibition of proteasome function. The Journal of Biological Chemistry, 281: pp.29228-29335. [Google Scholar] [Crossref]

25. Stark, L.A., Reid, K., Sansom, O.J., Din, F.V., Guichard, S., Mayer, I., Jodrell, D.I., Clarke, A.R. and Dunlop, M.G. (2007) Aspirin activates the NF-kappaB signalling pathway and induces apoptosis in intestinal neoplasm in two in vivo models of human colorectal cancer. Carcinogenesis, 28(5): pp.968-76 [Google Scholar] [Crossref]

26. Yun, Tian, Ying, Ye, Wei, GAO, Ting, Song, Daqing, Wang, Xiaoyun, Mao, Changshan and Ren, (2010) Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms involving downregulation of IL-6-STAT3 signalling pathway. International Journal of Colorectal Disease, pp.1432-1262. [Google Scholar] [Crossref]

27. Miner, J., & Hoffhines, A. (2007). The discovery of aspirin's antithrombotic effects. Texas Heart Institute Journal, 34(2), 179. [Google Scholar] [Crossref]

28. Ahmed, Alagha, Edemiro, Moman, Mauro, F.A., Adamo, Kelvin, B., Nolan and Anthony, J. (2009) Design, synthesis and evaluation of aspirin analogues having additional carboxylate substituent. Bioorganic and medicinal chemistry letters, 19(15): pp.4213-4216 [Google Scholar] [Crossref]

29. Alagha, A., Morgan, E., Adamo, M.E., Nolan, K.B. and Chubb, A.J. (2009) Design, synthesis and evaluation of aspirin analogues having an additional carboxylate substituent for antithrombotic activity. Bioorg Med Chem Lett, 119(15): pp.4213-6 [Google Scholar] [Crossref]

30. Thomas, R., Hundley and Basil, Rigas (2006) Nitric oxide donating aspirin inhibits colon cancer cell growth via mitogen activated protein kinase activation. JPET, 316(1): pp.25-34 [Google Scholar] [Crossref]

31. Chiu S.M., Xue, L.Y., Usuda, J., Azizuddin, K. and Oleinick, N.L. (2003) Bax is essential for mitochondrion-mediated apoptosis but not for cell death caused by photodynamic therapy. British Journal of Cancer, 89: pp.1590-1597 [Google Scholar] [Crossref]

32. Lin, Zhang, Jian, Yu, Ben, Ho, Park, Kenneth, W., Kinzler, Bert and Vogelston, (2000) Role of Bax in the apoptotic response to anticancer agents. Science, 290(5493): pp.989-992. [Google Scholar] [Crossref]

33. Lai, M.Y., Huang, J.A., Liang, Z.H., Jiang, H.X. and Tang, G.D. (2008) Mechanism underlying aspirin- mediated growth inhibition and apoptosis induction of cyclooxygenase-2 negative colon cancer cell line SW480. World J Gastroenterol, 14(26): pp.4227-33 [Google Scholar] [Crossref]

34. Teles, A.V.F.F., Rosenstock, C.S., Okuno, G.S., Lopes, C.R.A., Bertoncini and Smailli, S.S. (2008) Increase in bax expression and apoptosis are associated in Huntington disease progression. Posted online 27 March 2008 [Google Scholar] [Crossref]

35. Rothenberg, M.L. (2001) Irinotecan (CPT-11): recent development and future directions-colorectal cancer and beyond. Oncology, 6: pp.66-80 [Google Scholar] [Crossref]

36. Liu, L.F., Desai, S.D. and Li, T.K. (2000) Mechanism of action of camptothecin. Ann N Y Acad Sci, 922: pp.1-10 [Google Scholar] [Crossref]

37. Shao, R.G., Cao, C.X. and Zhang, H. (1999) Replication mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes. EMBO J, 18: pp.1397-1406 [Google Scholar] [Crossref]

38. Morris, E.J. and Geller, H.M. (1996) Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-1: evidence for cell cycleindependent toxicity. J Cell Biol, 134: pp.757-770 [Google Scholar] [Crossref]

39. Sheena, Derry, Yoon, Kong and Loke, (2000) Risk of gastrointestinal haemorrhage with long term use of aspirin: metal analysis. BMJ, 321: pp.1183 [Google Scholar] [Crossref]

40. Andrew, T., Chan, M.D., M.P.H., Edward, L., Giovannucci, M.D., ScD, Jeffrey, A., Mererhardt, M.D., MPH, Eva, S., Schernhammer, M.D., DrPH, Gary, C., Curhan, M.D, ScD and Charles, S. (2005) Long term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA, 294(8): pp.914-923 [Google Scholar] [Crossref]

41. McGovern, M.C., Glasgown, J.F.T. and Stewart, M.C. (2001) Reye’s syndrome and aspirin: less we forget. BMJ, 322: pp.1591 [Google Scholar] [Crossref]

42. D’Agati, V. (1996) Does aspirin causes acute or chronic renal failure in experimental animals and in human. American Journal of Kidney Disease, 28(1 Suppl 1): s24-9. [Google Scholar] [Crossref]

43. Frigas, E., & Park, M. A. (2009). Acute urticaria and angioedema: diagnostic and treatment considerations. American journal of clinical dermatology, 10(4), 239-250 [Google Scholar] [Crossref]

44. Grigoriadou, S., & Longhurst, H. J. (2009). Clinical immunology review series: an approach to the patient with angio-oedema. Clinical & Experimental Immunology, 155(3), 367-377. [Google Scholar] [Crossref]

• Development and Evaluation of Floating Alginate Beads of Esomeprazole
• Determination of pKa Value for Ranolazine and Atenolol Using UV Spectroscopy
• The Science of Sustained-Release Medications
• Development of Proteomics in Clinical Medicine
• Advances on Quinoline Derivatives: A Review of Synthesis and Biological Activities